GERN logoGERN
Geron Corp.

21,308
Loading...
Loading...
News
all
press releases
Geron (GERN) Reports Q2 Loss, Tops Revenue Estimates
Geron (GERN) delivered earnings and revenue surprises of +33.33% and +2.35%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·1mo ago
News Placeholder
More News
News Placeholder
Incyte (INCY) Surpasses Q2 Earnings and Revenue Estimates
Incyte (INCY) delivered earnings and revenue surprises of +12.95% and +5.56%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·2mo ago
News Placeholder
Geron Corporation Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights
Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer, today reported financial results for the fourth quarter...
Business Wire·7mo ago
News Placeholder
Geron to Participate at Upcoming Investor Conferences in March 2025
Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company, today announced that members of the management team are scheduled to participate in fireside chats at the following...
Business Wire·7mo ago
News Placeholder
Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Geron Corporation (Nasdaq: GERN), a commercial stage biopharmaceutical company, today reported that it has granted equity awards covering an aggregate of 180,000 shares of its common stock...
Business Wire·7mo ago
News Placeholder
2 Hot Growth Stocks Poised for Gains of Up to 370%, According to Wall Street
These biotech companies’ strategic advancements are setting them up for long-term success.
barchart.com·7mo ago
News Placeholder
Geron to Announce Fourth Quarter and Full-Year 2024 Financial Results on February 26, 2025
Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company, today announced that it will release its fourth quarter and full-year 2024 financial results and business highlights...
Business Wire·7mo ago
News Placeholder
Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Geron Corporation (Nasdaq: GERN), a commercial stage biopharmaceutical company, today reported that it has granted non-statutory stock options to purchase an aggregate of 72,000 shares of Geron...
Business Wire·9mo ago
News Placeholder
Geron Announces Positive CHMP Opinion for RYTELO (imetelstat) for the Treatment of Adults with Transfusion-Dependent Anemia due to Lower-Risk MDS
Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer, today announced that the Committee for Medicinal Products...
Business Wire·9mo ago
News Placeholder
Geron Announces New IMerge Analyses Presented at ASH Suggesting Clinical Activity of RYTELO (imetelstat) in Patients with Lower-Risk MDS Regardless of Type or Number of Prior Therapies
Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer, today announced new analyses presented at the 66th...
Business Wire·9mo ago

Latest GERN News

View

Advertisement. Remove ads.

Advertisement. Remove ads.